Targeting the MDM2-p53 interaction for cancer therapy

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5318-5324

  Shangary, Sanjeev ^a,b   Wang, Shaomeng ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYTARABINE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; IRINOTECAN; MDM2 INHIBITOR; MI 219; MI 63; NUTLIN 2; NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TAXANE DERIVATIVE; TDP 665759; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; BINDING AFFINITY; BREAST TUMOR; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON TUMOR; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; GENE ACTIVITY; GENE DELETION; GENE MUTATION; GENETIC CODE; HUMAN; LIVER TUMOR; LUNG TUMOR; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REED STERNBERG CELL; REVIEW; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASM;

DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53049108040     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5136     Document Type: Review

References (68)

1. TeodoroJG,EvansSK,Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of thegenome.J Mol Med2007;85:1175-86.
2. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40.
3. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
4. Lane DP, Crawford LV. Tantigen is bound to a host protein in SV40-transformed cells. Nature1979;278: 261-3.
5. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 1979;76:2420-4.
6. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-trans-formed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
7. OrenM,LevineAJ. Molecular cloning of acDNA spe-cific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci U S A 1983;80:56-9.
8. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
9. Koshland DE, Jr. Molecule of the year. Science1993;262:1953.
10. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004;52:103-16.
11. Fakharzadeh SS,Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor celll ine.EMBO J1991;10:1565-9.
12. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
13. Momand J, Jung D,Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res1998;26:3453-9.
14. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
15. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev1993;7:1126-32.
16. ChenJ,MarechalV,LevineAJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14.
17. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18:7288-93.
18. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
19. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature1995;378:206-8.
20. Montes de Oca Luna R,Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature1995;378:203-6.
21. Picksley SM,Vojtesek B, Sparks A, Lane DP. Immu-nochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994;9:2523-9.
22. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-53.
23. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128:837-40.
24. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31.
25. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006;13:921-6.
26. Vassilev LT,Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science2004;303:844-8.
27. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-93.
28. Sarek G, Kurki S, Enback J, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.J Clin Invest 2007;117:1019-28.
29. Koblish HK, Zhao S, Franks CF, et al. Benzodiazepi-nedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther2006;5:160-9.
30. Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005;48:909-12.
31. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-baseddesign of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005;127:10130-1.
32. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-53 interaction. J Med Chem 2006;49:3432-5.
33. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008;105:3933-8.
34. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006;281:33030-5.
35. Patton JT, Mayo LD, Singhi AD, GudkovAV, Stark GR,Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-76.
36. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006;281:33036-44.
37. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-6.
38. ThompsonT,Tovar C,Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004;279:53015-22.
39. Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001;268:2784-91.
40. Efeyan A, Ortega-Molina A,Velasco-Miguel S, Herranz D,Vassilev LT, Serrano M. Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin. Cancer Res 2007;67:7350-7.
41. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
42. Potten CS, Wilson JW, Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells1997;15:82-93.
43. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006;10:501-14.
44. Bottger V, Bottger A, Garcia-Echeverria C, et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene1999;18:189-99.
45. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 2003;278:45946-53.
46. Lau LM, NugentJK,Zhao X,Irwin MS. HDM2 antagonist Nutlin-3 disruptsp73-2 binding and enhancesp73 function. Oncogene 2008;27:997-1003.
47. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2 F1. Oncogene2007;26:3473-81.
48. LaRusch GA,Jackson MW,DunbarJD,Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endo-thelial growth factor induction by preventing the interaction between hypoxia inducible factor 1 α and Hdm2. Cancer Res 2007;67:450-4.
49. Colaluca IN,Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature 2008;451:76-80.
50. Secchiero P, Corallini F, Gonelli A, et al. Antiangio-genic activity of the MDM2 antagonist nutlin-3. Circ Res2007;100:61-9.
51. Binder BR. A novel application for murine double minute 2 antagonists: the p53 tumor suppressor network also controls angiogenesis. Circ Res 2007;100:13-4.
52. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α Genes Dev 2000;14:34-44.
53. Carvajal D,Tovar C,Yang H,Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005;65:1918-24.
54. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000.
55. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies P53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood2007;111:1584-93.
56. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-9.
57. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008;7:1604-12.
58. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
59. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26:1317-23.
60. Cattelani S, Defferrari R, Marsilio S, et al. Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients. Clin Cancer Res 2008;14:3248-53.
61. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer DrugTargets2005;5:27-41.
62. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:4122-9.
63. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leuke-miacells. Blood2006;107:4109-14.
64. Secchiero P, Zerbinati C, di Iasio MG, et al. Syner-gistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nut-lin-3inacutemyeloidleukemiacells.CurrDrugMetab 2007;8:395-403.
65. Drakos E,Thomaides A, Medeiros LJ, et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007;13:3380-7.
66. Kranz D, Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res2006;66:10274-80.
67. Yang H, Filipovic Z, Brown D, Breit SN,Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol CancerTher 2003;2:1023-9.
68. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34.